The Charles Bronfman Institute for Personalized Medicine

BioMe® Biobank

The Charles Bronfman Institute for Personalized Medicine is revolutionizing medicine and health care based on your personal DNA and data. Our world-class faculty is leading the way in discovering genetic underpinnings of common diseases and in advancing genome-informed medicine at the Mount Sinai Health System.

In the News

Oct 21, 2021

Mount Sinai Leader Awarded 2021 Sherman Prize for Advancements in Understanding IBD Genetics

The Bruce and Cynthia Sherman Charitable Foundation has announced Judy H. Cho, MD as a recipient of the 2021 Sherman Prize, which recognizes excellence in the field of Crohn’s disease and ulcerative colitis, two forms of inflammatory bowel disease (IBD).

Jun 07, 2021

New Division of Data Driven and Digital Medicine Within the Department of Medicine

We are pleased to announce the establishment of a new Division of Data Driven and Digital Medicine within the Department of Medicine at the Icahn School of Medicine at Mount Sinai. Led by Girish N. Nadkarni, MD, the Division’s mission is to create a data science and digital health hub to catalyze translational research.

Jun 05, 2021

Non-Invasive Ventilation Versus Mechanical Ventilation in Hypoxemic Patients with COVID-19

Forrest IS, Jaladanki SK, Paranjpe I, Glicksberg BS, Nadkarni GN, Do R. Infection. 2021 Jun 5:1-9. doi: 10.1007/s15010-021-01633-6. Online ahead of print. PMID: 34089483

May 19, 2021

How COVID-19 Long-Haulers Can Get Back to Physical Activity

As part of our COVID-19 Long-Hauler study, this shows COVID-related symptoms weighted by the number of BioMe participants for whom those symptoms were still being discussed 90 days following COVID-19 diagnosis, when never mentioned for those participants prior to two weeks before diagnosis, so as to ignore preexisting symptoms. While we have data on 2604 Covid+ patients in BioMe, this represents 681 participants who had notes available 90 days post-diagnosis." -Tielman Van Vleck, IPM Associate Computational Scientist and BioMe Co-Investigator

Apr 01, 2021

Understanding Acute Kidney Injury as a Complication of COVID-19

Lili Chan & Girish N Nadkarni #nephrology #covid19 #NadkarniLab #MountSinaiCOVIDInformaticsCenter

Mar 31, 2021

A Myeloid–Stromal Niche and GP130 Rescue in NOD2-driven Crohn’s Disease

New study identifies a new approach that will help personalize treatment for patients diagnosed with Crohn’s disease. #judycho #chrohns

Mar 15, 2021

Sanford J. Grossman Charitable Trust Pledges $5.9 Million to Establish Interdisciplinary Center in Neural Circuitry and Immune Function at Mount Sinai

The Sanford J. Grossman Charitable Trust, founded by renowned economist and philanthropist Sanford J. Grossman, PhD, has committed $5.9 million to establish the Sanford Grossman Interdisciplinary Center in Neural Circuitry and Immune Function at the Icahn School of Medicine at Mount Sinai.

Feb 01, 2021

Effect of Sickle Cell Trait and APOL1 Genotype on the Association of Soluble uPAR with Kidney Function Measures in Black Americans

Soluble urokinase plasminogen activator receptor (suPAR) is the circulating form of urokinase plasminogen activator receptor, a glycosyl-phosphatidylinositol–anchored membrane protein expressed in various cell types including kidney podocytes and endothelial cells.

Jan 29, 2021

Major Grant Enables Top Researcher to Put Down Roots in Denmark

IPM researcher Professor Ruth Loos was offered the opportunity to join the NNF Center for Basic Metabolic Research and awarded seven-year DKK50 million Laureate Research Grant from the Novo Nordisk Foundation.

Jan 27, 2021

Integrated Spatial Genomics Reveals Global Architecture of Single Nuclei

Identifying the relationships between chromosome structures, nuclear bodies, chromatin states and gene expression is an overarching goal of nuclear-organization studies.

Dec 04, 2020

Robust Neutralizing Antibodies to SARS-CoV-2 Infection Persist for Months

BioMe called “heroes” for providing 360 de-identified plasma samples to Mount Sinai’s Department of Pathology, Molecular and Cell-based Medicine to help “define the normal level of Cytokines and anti COVID19 Antibodies required by the NYSDOH Wadsworth Center.”

Nov 23, 2020

Discovery of Rare Variants Associated with Blood Pressure Regulation Through Meta-analysis of 1.3 Million Individuals

Genetic studies of blood pressure (BP) to date have mainly analyzed common variants (minor allele frequency > 0.05).

Oct 23, 2020

Autoantibodies Against Type I IFNs in Patients with Life-Threatening COVID-19

Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast.

Oct 19, 2020

BioMe Principal Investigator Elected to the National Academy of Medicine

The National Academy of Medicine (NAM) is a leading organization dedicated to promoting science, health equity, and trusted medical advice nationally and globally in order to broadly promote human health. For these reasons, I am deeply honored to have been elected to NAM. This recognition substantially reflects the impact of BioMe as a forward-looking research endeavor committed to rapidly applying research advances to improve patient health. On a personal level, I am a participant in BioMe; by volunteering, each of us can advance knowledge to improve outcomes for ourselves and others.

Jun 15, 2020

Human CRY1 Variants Associate with Attention Deficit/Hyperactivity Disorder

Recent study published in the JCI, the Itan lab demonstrated a good use of BioMe Biobank samples where they performed PheWAS analyses in BioMe Biobank samples to support the evidence that mutations in the gene CRY1 are associated with ADHD and insomnia

Jun 09, 2020

Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease

Polygenic risk scores (PRS) for coronary artery disease (CAD) identify high-risk individuals more likely to benefit from primary prevention statin therapy.

Twitter

Loading Tweets...

Videos

View All Videos

BioMe: Channeling the power of genomics and BIG data

PharmaCoGenomics at Mount Sinai Health System in New York City

Mount Sinai Innovation in Devices, Diagnostics & Clinical Trials - SINAInnovations 2012 Conference

Whole Genome Sequencing and You

Introduction to the Charles Bronfman Institute for Personalized Medicine

Mount Sinai Receives TOPMed Grant For BioMe BioBank

BioMe BioBank

Meet Our Team

Featured Labs

Loos Lab

Gaining insight in the biology that controls body weight

Loos Lab

Gaining insight in the biology that controls body weight

Cho Lab

Investigating genetic and immunologic factors associated with inflammatory bowel disease

Kenny Lab

Analyzing human genetic variation to address questions in biology, medicine, and anthropology

Latest Publications

Judy H. Cho, MD
The Promise of Epigenetics: Has it Delivered New Insights?

Ron Do, PhD
Rare Variant in Scavenger Receptor BI Raises HDL Cholesterol and Increases Risk of Coronary Heart Disease

Eimear Kenny, PhD
GBStools: A Statistical Method for Estimating Allelic Dropout in Reduced Representation Sequencing Data

Ruth Loos, PhD
Testing the Role of Predicted Gene Knockouts in Human Anthropometric Train Variation

Girish Nadkarni, MD, MPH
Genomics in CKD: Is This the Path Forward?

Aniwaa Owusu Obeng, PharmD
Genetic Variation among 82 Pharmacogenes: The PGRN-Seq Data From the eMERGE Network

Stuart Scott
Polygenic Overlap Between Schizophrenia Risk and Antipsychotic Response: A Genomic Medicine Approach

Inga Peter
Mutation Screening of Candidate Genes in Patients With Nonsyndromic Sagittal Craniosynostosis

View All Publications

Contact the Institute